Aarti Pharmalabs Limited announced its audited financial results for the quarter and year ended March 31, 2026. The revenue from operations for the quarter ended March 31, 2026, was Rs 57,970.05 lakhs, showing a growth of 36.32% compared to the previous quarter (Rs 42,525.28 lakhs) and a growth of 9.46% compared to the corresponding quarter of the previous year (Rs 52,962.37 lakhs). The net profit for the quarter ended March 31, 2026, was Rs 6,203.07 lakhs, reflecting a growth of 44.52% compared to the previous quarter (Rs 4,292.18 lakhs) and a decline of 30.18% compared to the corresponding quarter of the previous year (Rs 8,884.52 lakhs).

Aarti Pharmalabs Limited is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company operates primarily within the pharmaceutical segment and is known for its research-based solutions and global supply chain presence. As of May 25, 2026, the company has announced key appointments in its senior management, including the Head of Exports and the Head of Operations & Compliance, to strengthen its leadership team. Additionally, the Board has recommended a final dividend of Rs 2 per equity share for the financial year ended March 31, 2026.